A Randomized, Double-Blind, Placebo-Controlled, Parallel, 4-Arm Dose Ranging Study of the Safety and Efficacy of Nalbuphine Extended-Release Tablets (NAL ER) for the Treatment of Cough in Idiopathic Pulmonary Fibrosis (IPF)
CompletedCTIS2023-505296-72-00
Trevi Therapeutics Inc.Idiopathic Pulmonary Fibrosis (IPF)
Start: 2023-12-12End: 2025-04-23Target: 90Updated: 2025-01-13